Versor Investments LP Takes $217,000 Position in AtriCure, Inc. (NASDAQ:ATRC)

Versor Investments LP purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 7,100 shares of the medical device company’s stock, valued at approximately $217,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. State Street Corp increased its holdings in AtriCure by 4.9% during the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock worth $37,710,000 after acquiring an additional 63,002 shares during the period. Geode Capital Management LLC increased its holdings in AtriCure by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock worth $32,326,000 after acquiring an additional 32,676 shares during the period. Atom Investors LP bought a new stake in AtriCure during the 3rd quarter worth approximately $1,741,000. Silver Oak Securities Incorporated bought a new stake in AtriCure during the 4th quarter worth approximately $220,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in AtriCure by 31.5% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock worth $14,038,000 after acquiring an additional 119,929 shares during the period. Institutional investors own 99.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ATRC. Piper Sandler upped their target price on shares of AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. upped their target price on shares of AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Stifel Nicolaus upped their target price on shares of AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Canaccord Genuity Group increased their price target on shares of AtriCure from $61.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $51.00 price target on shares of AtriCure in a report on Thursday, February 13th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $51.56.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $38.16 on Wednesday. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -40.17 and a beta of 1.46. The company’s fifty day moving average price is $37.52 and its 200-day moving average price is $32.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.